Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/15/2025

Rheumatoid Arthritis Treatment Guidelines

Introduction to Treatment

  • Rheumatoid arthritis (RA) treatment should be initiated as soon as diagnosis is made, with methotrexate (MTX) as the cornerstone first-line DMARD, as recommended by the American College of Rheumatology and the European League Against Rheumatism 1, 2
  • The target optimal dosing of MTX is up to 25 mg weekly, with alternatives including leflunomide and sulfasalazine for MTX contraindications or intolerance, as suggested by the European League Against Rheumatism and the American College of Rheumatology 1, 3, 2

First-line and Second-line Therapies

  • Methotrexate (MTX) remains the primary first-line DMARD for active RA, with low-dose glucocorticoids considered as bridge therapy for up to 6 months, with tapering as rapidly as clinically feasible 1, 2
  • For patients without poor prognostic factors, switching to or adding another conventional synthetic DMARD (csDMARD) is recommended, as suggested by the European League Against Rheumatism 1, 2, 4
  • Available csDMARDs include leflunomide, sulfasalazine, and hydroxychloroquine, with the option to combine them for improved efficacy 1, 3, 2

Third-line Therapy and Efficacy of Biologic DMARDs

  • In patients with poor prognostic factors (RF/ACPA positivity, high disease activity, early joint damage), adding a biological DMARD (bDMARD) or JAK inhibitor to MTX is suggested, with options including TNF inhibitors, IL-6 receptor blockers, T-cell costimulation inhibitors, and anti-B-cell agents, as recommended by the European League Against Rheumatism and the American College of Rheumatology 1, 2, 4
  • Available bDMARDs include:

    bDMARD Mechanism of Action
    Adalimumab TNF inhibitor
    Certolizumab TNF inhibitor
    Etanercept TNF inhibitor
    Golimumab TNF inhibitor
    Infliximab TNF inhibitor
    Tocilizumab IL-6 inhibitor
    Sarilumab IL-6 inhibitor
    Abatacept T-cell co-stimulation modulator
    Baricitinib JAK inhibitor
    Tofacitinib JAK inhibitor
    Upadacitinib JAK inhibitor
  • If the first bDMARD fails, switching to another bDMARD is recommended, with the option to use another TNF inhibitor or a biological agent with another mode of action, as advised by the European League Against Rheumatism 2

Safety Concerns and Monitoring

  • Tofacitinib is associated with increased risk of infections, particularly herpes zoster, and potential cardiovascular risks, emphasizing the importance of regular monitoring for infections, complete blood count, liver function tests, lipid profile, and renal function, as recommended by the European League Against Rheumatism 2
  • Patients on tofacitinib should be monitored for infections, particularly herpes zoster, which occurs at higher rates than with TNF inhibitors, and laboratory parameters, including lymphocytopenia and anemia, should be monitored regularly, as advised by the European League Against Rheumatism 2
  • The European League Against Rheumatism recommends assessing response every 1-3 months in active disease and adjusting therapy if no improvement by 3 months or target not reached by 6 months, with monitoring frequency every 1-3 months in active disease and every 6-12 months once target is reached 1, 3, 2
  • Screen for tuberculosis before starting bDMARDs, and ensure optimal dosing of methotrexate (up to 25 mg weekly) before declaring treatment failure, as recommended by the European League Against Rheumatism and the American College of Rheumatology 1, 5, 2

Special Considerations

  • Patients with rheumatoid factor (RF) or anti-citrullinated protein antibody (ACPA) positivity, high disease activity, early joint damage, or failure of 2 or more csDMARDs may require more aggressive treatment, according to the American College of Rheumatology 1
  • bDMARDs and tsDMARDs should be combined with a csDMARD (typically MTX), with the option to use IL-6 inhibitors and JAK inhibitors for patients who cannot use csDMARDs as comedication, as suggested by the European League Against Rheumatism and the American College of Rheumatology 1
  • Common pitfalls to avoid include delaying DMARD initiation, inadequate MTX dosing, insufficient monitoring, prolonged glucocorticoid use, and overlooking prognostic factors, as advised by the European League Against Rheumatism and the American College of Rheumatology 1